Clinic Roundup

Targacept Inc., of Winston-Salem, N.C., reported data from a Phase II trial showing that its schizophrenia candidate TC-5619 caused statistically significant superiority over placebo for cognitive dysfunction in schizophrenia and negative symptoms of schizophrenia. In the trial, 185 patients with schizophrenia, having stable psychotic symptoms and taking an approved atypical antipsychotic medication, received TC-5619 or placebo in addition to their antipsychotic, for 12 weeks. The drug was well tolerated with nausea as its most frequent adverse event.